不稳定性心绞痛（UA）诊断和治疗建议-中华医学会心血管病学分会PPT.ppt

* Slide 23 CURE – Substudies In addition to the main CURE trial, a number of substudies are being conducted that will provide important additional information. EPI-CURE is an epidemiologic study that will include a cohort of CURE patients with non-ST elevation ACS, cases of unstable angina, new cases of acute transmural MI and matched controls. The objective is to understand better the genetic and pathophysiological mechanisms and the risk factors for ACS. PCI-CURE will assess the CURE patients who undergo PCI, with special reference to the benefits of clopidogrel. COAG-CURE will assess the effect of clopidogrel in suppressing coagulation markers. The Millennium survey will collect data on practise patterns in consecutive patients with unstable angina or MI at centers participating in CURE. Reference CURE Study Investigators. Eur Heart J 2000;21:2033–2041. * Slide 24 Baseline Characteristics This table shows the baseline clinical characteristics in all 12 564 patients randomized into CURE. The mean age is 64.2 years and 38.5% of the patients are female. Patients were randomized after a mean duration of symptoms of 14.1 hours. A large proportion of patients had a previous history of ischemic events (MI, stroke, PCI). The population was therefore representative of unstable angina and non-Q-wave MI patients. The majority of the patients (74.8%) had an entry diagnosis of unstable angina. Reference CURE Study Investigators. Eur Heart J 2000;21:2033–2041. * Slide 25 Baseline Characteristics – ECG Abnormalities More than 92% of patients had an abnormal ECG at study entry, with ST depression 1 mm being the commonest abnormality. Overall, the baseline demographic data indicate that this is at least a moderate risk group of patients with unstable angina or non-Q-wave MI. Reference CURE Study Investigators. Eur Heart J 2000;21:2033–2041. * Slide 8 CURE – Concomitant Medications After Randomization Patients in CURE were receiving optimal medical management